Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Celsentri

CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-118467 · Präparat HOS-094825

Ritonavir AUC12: ↔ 0.93 Ritonavir Cmax: ↔ 1.02 Ritonavir C12: ↓ 0.74 Etravirine and Not studied. Based on the extent of lopinavir/ritonavir, inhibition by lopinavir/ritonavir, saquinavir/ritonavir or saquinavir/ritonavir or atazanavir/ritonavir atazanavir/ritonavir in the absence of etravirine, an increased exposure is expected. ANTIBIOTICS Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg Trimethoprim Maraviroc Cmax: ↔ 1.19 twice daily and 800 mg/160 mg BID Sulphamethoxazole/trimethoprim sulphamethoxazole/ (maraviroc 300 mg BID) concentrations not measured, no trimethoprim can be effect expected. co-administered without dose adjustment. Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should (maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 be increased to 600 mg Rifampicin concentrations not twice daily when measured, no effect expected. co-administered with rifampicin in the absence of a potent CYP3A4 inhibitor. This dose adjustment has not been studied in HIV patients. See also section 4.4. Rifampicin + efavirenz Combination with two inducers has Concomitant use of not been studied. There may be a risk CELSENTRI and of suboptimal levels with risk of loss rifampicin + efavirenz is of virologic response and resistance not recommended. development.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) trimethoprim (HOS-085184) etravirine (HOS-088088) saquinavir (HOS-084522) efavirenz (HOS-087947) ritonavir (HOS-084521)